Genotype–phenotype correlations and novel molecular insights into the *DHX30*-associated neurodevelopmental disorders

Ilaria Mannucci, MSc[1], Nan Cher Yeo, PhD[2], Hannes Huber, MSc[3], Jaclyn B. Murry, PhD[4,5], Jeff Abramson, PhD[6], Thorsten Althoff, PhD[6], Siddharth Banka, MD, PhD[7,8], Gareth Baynam, PhD[9,10,11], David Bearden, MD[12], Ana Beleza, MD, PhD[13], Paul J. Benke, MD[14], Siren Berland, MD[15], Tatjana Bierhals, MD[1], Frederic Bilan, PhD[16,17], Laurence A. Bindoff, MD, PhD[18,19], Geir Julius Braathen, MD, PhD[20], Øyvind L. Busk, PhD[20], Jirat Chenbhanich, MD[21], Nghi D. P. Dang, MSc[2], Jonas Denecke, MD[22], Luis F. Escobar, MD[23], Caroline Estes, MSc, CGC[23], Julie Fleischer, MD[24], Daniel Groepper, MSc[24], Charlotte A. Haaxma, MD, PhD[25], Maja Hempel, MD[1], Yolanda Holler-Managan, MD[26], Gunnar Houge, MD, PhD[15], Adam Jackson, MSc[7,8], Laura Kellogg, MSc[27], Boris Keren, MD, PhD[28], Catherine Kiraly-Borri, MD[29], Cornelia Kraus, PhD[30], Christian Kubisch, MD[1], Gwenael Le Guyader, MD[16,17], Ulf W. Ljungblad, MD[31], Leslie Manace Brenman, MD[32], Julian A. Martinez-Agosto, MD, PhD[5, 33, 34, 35], Matthew Might, PhD[36], David T. Miller, MD, PhD[37], Kelly Q. Minks, MSc[12], Billur Moghaddam, MD[27], Caroline Nava, MD, PhD[28], Stanley F. Nelson, MD[5,35, 38], Trine Prescott, MD[20], Farrah Rajabi, MD[37], Hanitra Randrianaivo, MD[39], Simone F. Reiter, MD, PhD[15], Janneke Schuurs-Hoeijmakers, MD, PhD[40], Perry B. Shieh, MD, PhD[41], Anne Slavotinek MBBS, PhD[21], Sarah Smithson, MD[13], Alexander P.A Stegmann, PhD[40,42], Kinga Tomczak, MD, PhD[43], Kristian Tveten, PhD[20], Jordan H. Whitlock, BSc[36], Christiane Zweier MD, PhD[30], Kirsty McWalter, MSc, CGC[44], Jane Juusola, PhD[44], Fabiola Quintero-Rivera, MD[4,4,45], Utz Fischer, PhD[3], Hans-Jürgen Kreienkamp, PhD[1*], Davor Lessel, MD, PhD[1*]

[1]Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

[2]Department of Pharmacology and Toxicology, Hugh Kaul Precision Medicine Institute, University of Alabama, Birmingham, USA

[3]Department of Biochemistry, Theodor Boveri Institute, Biocenter of the University of Würzburg, 97070 Würzburg, Germany

[4]Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

[5]UCLA Clinical Genomics Center, University of California Los Angeles, Los Angeles, California, USA

[6]Department of Physiology, University of California Los Angeles, Los Angeles, CA, USA
[7]Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK

[8]Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

[9]Faculty of Medicine and Health Sciences, University of Western Australia, Perth, WA, Australia.

[10]Western Australian Register of Developmental Anomalies, King Edward Memorial Hospital, Perth, Australia

[11]Telethon Kids Institute, Perth, Australia

[12]Division of Child Neurology, Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA.

[13]Department of Clinical Genetics, University Hospitals, Bristol, UK.

[14]Joe DiMaggio Children's Hospital, Florida, USA

[15]Department of Medical Genetics, Haukeland University Hospital, Bergen 5021, Norway.

[16]Department of Medical Genetics, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

[17]EA 3808 NEUVACOD, Université de Poitiers, Poitiers, France.

[18]Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.

[19]Department of Neurology, Haukeland University Hospital, Bergen, Norway.

[20]Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway

[21]Division of Medical Genetics, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.

[22]Department of Pediatrics, University Medical Center Eppendorf, 20246 Hamburg, Germany

[23]Peyton Manning Children's Hospital, Ascension Health, Indianapolis Indiana, USA

[24]Department of Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois, 62702, USA.

[25]Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands

[26]Division of Neurology, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

[27]Kaiser Permanente Sacramento, Sacramento, USA

[28]Département de Génétique, Hôpital La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.

[29]Genetic Services of Western Australia, Perth, Western Australia 6008, Australia.

[30]Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.

[31]Department of Pediatrics, Vestfold Hospital, Tønsberg, 3116, Norway.

[32]Kaiser Permanente Northern California, Department of Genetics, Oakland, USA.

[33]Semel Institute of Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA

[34]Department of Pediatrics, Division of Medical Genetics at David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

[35]Department of Human Genetics at David Geffen School of Medicine University of California Los Angeles, Los Angeles, California, USA

[36]Department of Medicine, Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, 510 20th St S, Birmingham, AL 35210, USA.

[37]Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts.

[38]Center for Duchenne Muscular Dystrophy, University of California Los Angeles, Los Angeles, California, USA

[39]UF de Génétique Médicale, GHSR, CHU de La Réunion, Saint Pierre, La Réunion, France.

[40]Department of Human Genetics, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands

[41]Department of Neurology at David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

[42]Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.

[43]Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.

[44]GeneDx, Gaithersburg, MD 20877, USA.

[45]Department of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA, USA.

[*]Correspondence should be addressed to H-J.K (kreienkamp@uke.de) or D.L (d.lessel@uke)

Abstract

Background

We aimed to define the clinical and mutational spectrum, and to provide novel molecular insights into *DHX30*-associated neurodevelopmental disorder.

Methods

Clinical and genetic data from affected individuals were collected through family support group, GeneMatcher and our network of collaborators. Novel missense variants were investigated by *in-vitro* and *in-vivo* assays. These analyses included investigation of stress granule formation, global translation, ATPase and helicase activity, as well as the effect of selected variants on embryonal development in Zebrafish.

Results

We identified altogether 25 previously unreported individuals. All 19 individuals harboring heterozygous missense variants within helicase core motifs (HCMs) have global developmental delay, intellectual disability, severe speech impairment and gait abnormalities. These variants impair the ATPase and helicase activity of DHX30 and global translation, trigger stress granule formation, and cause developmental defects in a zebrafish model. Notably, 4 individuals harboring heterozygous variants resulting either in haploinsufficiency or truncated proteins presented a milder clinical course, similar to an individual bearing a *de novo* mosaic missense variant within HCM. Late-onset severe ataxia was observed in an individual with a *de novo* missense variant within the ratchet-like domain, and early-onset lethal epileptic encephalopathy in an individual with a homozygous missense variant within the helicase core region but not within a HCM. We report ten novel variants, two of which are recurrent, and provide evidence of gonadal mosaicism in one family. Functional analyses confirmed pathogenicity of all missense variants, and suggest the existence of clinically distinct subtypes that correlate with their location and nature. Moreover, we established here DHX30 as an ATP-dependent RNA helicase.

Conclusions

Our study highlights the usefulness of social media in order to define novel Mendelian disorders, and exemplifies how functional analyses accompanied by clinical and genetic findings can define clinically distinct subtypes for ultra-rare disorders. Such approaches require close interdisciplinary collaboration between families/legal representatives of the affected, clinicians, molecular genetics diagnostic laboratories and research laboratories.

BACKGROUND

RNA helicases (RH) are highly specialized proteins which use ATP hydrolysis for the unwinding of RNA secondary structures and the remodeling of ribonucleoprotein particles (RNPs).[1, 2] RHs are classified into six known superfamilies based on their sequence and structure.[1] Among these, the large helicase superfamily 2 (SF2) contains more than 50 members in humans.[3] These are designated DDX and DHX proteins based on the consensus amino acid sequence DExD or DExH signature in their ATP-binding motif II (Walker B motif).[3] All SF2 RNA helicases are built around a highly conserved helicase core region consisting of two domains that resemble the bacterial recombination protein recombinase A (referred to as RecA-1 and RecA-2). Within these two core helicase domains, eight highly conserved sequence elements, helicase core motifs (HCMs) play a role in either RNA binding, or ATP binding and hydrolysis. The roles of SF2 RNA helicases include regulation of splicing, nuclear mRNA export, translation, transcription, mRNA decay, microRNA processing, and cytoplasmic transport and storage of RNAs.[1] Thus far, many of the RHs have been studied in various cancers revealing the role of translation in carcinogenesis[4], and serve as potential biomarkers for diagnosis and prognosis, and novel drug targets.[5] The importance and functional relevance of certain SF2 RHs in human neurodevelopment is demonstrated by the identification of pathogenic germline variants in *DDX3X[6], DDX6[7], DHX30[8]* and *DDX59*[9] in individuals with neurodevelopmental disorders. Additionally, a paralog-based study implicated a role for *DHX16*, *DHX34*, *DHX37* and *DDX54*, in human neurodevelopmental disorders and suggested that *DHX8*, *DDX47* and *DHX58* may also be neurodevelopmental genes.[10]

Previously, we reported 12 unrelated individuals, with global developmental delay (GDD), intellectual disability (ID) accompanied by severe speech impairment and gait abnormalities, harboring one of six different *de novo* missense variants located within highly conserved HCMs of *DHX30*.[8] Moreover, a recent study reported gonadal mosaicism in two brothers carrying a *de novo* missense variant, p.(Ser737Phe), which resides within a HCM.[11] Here, we performed clinical, genetic and functional analyses to provide further understanding of *DHX30*-related neurodevelopmental disorders through the identification of 25 previously unreported individuals with pathogenic *DHX30* variants. This systematic clinical and research laboratory approach, partially facilitated through social media, provides evidence for novel genotype-phenotype correlations based on *in-depth* functional analyses accompanied by clinical and genetic findings.

MATERIALS AND METHODS

Human subjects and genetic analyses

The study was performed in accordance with protocols approved by the respective ethics committees of the institutions involved in this study (approval number by the Ethics Committee of the Hamburg Chamber of Physicians: PV 3802 and the UCLA IRB: 11-001087).Next-generation sequencing based analyses were performed in various independent research or diagnostic laboratories worldwide, using standard approaches described in the supplementary data (more details are available upon request). Most individuals were enrolled in the present study through the "*DHX30 family support group*" on Facebook: https://www.facebook.com/groups/1808373282809332. In such a case the families/legal representatives were asked to provide the contact details of attending physician/physicians in order to obtain objective and accurate clinical and genetic data. Others presented in the University Medical Center Eppendorf, Hamburg, Germany, or were recruited through GeneMatcher[12] and our network of collaborators. For all individuals, clinical data and information on genetic testing were uniformly obtained from attending physicians using a structured clinical table (Table S1) and clinical summary (Supplementary data).

Cell culture and *in-vitro* assays

Human embryonic kidney 293T (HEK 293T) cells and human bone osteosarcoma epithelial (U2OS) cells were grown under standard condition as described previously.[8] DXH30 expression vectors based on pEGFP-C3 (leading to an N-terminal GFP-tag) and pEGFP-N2 (for expression of the mitochondrial form of DHX30 with a C-terminal GFP-tag) have been described. Newly identified missense variants were introduced into both vectors using Quick-Change II site directed mutagenesis kit (Agilent, Waldbronn, Germany.[8] Transient transfection of HEK293T and U2OS cells, ATPase assay (in HEK293T), and immunocytochemistry and puromycin incorporation assay (in U2OS) were performed as previously described.[8]

Helicase assay

6xHis-SUMO-DHX30 wild-type and mutant proteins were expressed in the E. coli BL21 (DE3) pLysSpRARE cells (Novagen, Germany).Proteins were purified from lysates using Ni-NTA beads (Qiagen, Germany) as previously described.[13] To test the RNA unwinding activity of DHX30, a $[^{32}P]$-Labeled RNA duplex was synthesized using the T7 RNA polymerase from a linearized DNA template designed by Tseng-Rogenski and Chang.[14] Helicase activity was measured in 20 µl of reaction mixture containing 0.13 pmol of purified protein (=20 ng of full length protein), 25 fmol $[^{32}P]$-labeled RNA duplex,[14] 17 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM MgCl2, 2 mM DTT, 1 mM spermidine, 0.3% PEG8000, 5% glycerol, 150 mM KCl, 20 units of RNasin™ Plus (Promega, USA), 1 mM ATP. The mixture was incubated for 1h at 37°C, mixed with 2X non-denaturing loading dye and subjected to gel electrophoresis through non-denaturing 8% PAGE (19:1) in 0.5X TBE at 4°C. Reaction products were visualized by autoradiography. For more information see Supplementary data.

Construction of Tol2 plasmids

DHX30 cDNA plasmids were assembled using the Tol2 MultiSite Gateway® kit (Invitrogen, USA). Briefly, the cDNA of the wild-type DHX30 and DXH30 containing respective missense variants were amplified from the pEGFP-C3-DHX30 plasmids, using primers containing the appropriate att site sequences for BP recombination reactions. PCR products were purified and cloned into a pDONR221 donor vector using BP Clonase II enzyme mix following the manufacturer's manual. The resultant middle entry clones pME-DHX30 were purified and verified by direct sequencing. To assemble the final expression plasmids, p5E-tuba1a promoter and pME-DHX30 were cloned into a Tol2-based destination vector, pDestTol2CG2 containing cmlc2:egfp transgenesis marker, using LR Clonase II Plus enzyme mix following the manufacturer's instructions. The resultant pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 were purified and verified by direct sequencing.

Zebrafish maintenance and manipulation.

Tol2 transposase mRNA were synthesized using mMESSAGE mMACHINE™ T7 Transcription Kit (Ambion) per manufacturer's instructions. 25ng/ul Tol2 mRNA and 25ng/ul of pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 DNA were injected into 1-cell stage zebrafish, AB strain, embryos. To investigate potential dominant-negative effect 25ng/ul Tol2 mRNA and 25ng/ul equal mixture of pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 with the respective variant DNA were injected into 1-cell stage zebrafish embryos. The embryos were raised and scored for abnormal development 1-7 days post fertilization. Zebrafish were maintained in the Zebrafish Research Facility at the University of Alabama at Birmingham using standard protocols. All animal studies were performed according to the guidelines approved by the Institutional Animal Care and Use Committee of the University of Alabama, Birmingham.

RESULTS

Identification of likely pathogenic variants in *DHX30*

We identified 25 individuals carrying likely pathogenic variants in *DHX30* (Fig. 1). Of these, 12 individuals carry a previously reported heterozygous missense variant localizing within highly conserved helicase core motifs (HCMs): p.(Arg493His), p.(His562Arg), p.(Arg782Trp) (5 individuals including two half-sisters indicative of gonadal mosaicism), p.(Arg785Cys) (4 individuals) and p.(Arg785His). Further, 7 individuals have a novel heterozygous missense variant, each of which alters a highly conserved amino acid within a HCM predicted to be responsible for ATP binding and/or hydrolysis (Fig. 1 and Fig. S1). p.(Gly462Glu) identified in a single individual affects motif I, also referred to as Walker A motif, that binds γ phosphate and coordinates, together with motifs II and VI, ATP binding and hydrolysis in other DExH family members.[15, 16] p.(Ala734Asp) identified in two unrelated individuals, one of which (individual 6) appears to have mosaicism for the variant (Fig. S2), and p.(Thr739Ala) identified in a single individual, both affect motif V which regulates both ATP binding and/or hydrolysis and RNA binding.[2, 16] Three individuals carry p.(Arg782Gln), located within motif VI affecting the identical arginine residues, p.(Arg782Trp) that we previously reported[8] and which was identified here in five additional individuals.

Moreover, a homozygous variant p.(Arg725His) located within the helicase core region albeit between motifs IV and V, unlike all the missense variants mentioned above, was identified in individual 4. Additionally, a heterozygous *de novo* variant p.(Arg908Gln), the only not located within the helicase core region, was identified in individual 21. Prediction based on homology to other SF2 helicases,[15] [17] and published structures of the Prp43[18] and Mle[19] revealed three novel highly conserved C-terminal regulatory domains (CTD). These include a winged helix (WH), a ratchet-like (RL) and an oligosaccharide binding (OB) fold domain (Fig. 1) with a potential role in coupling ATP hydrolysis to RNA unwinding.[20] Notably, the p.(Arg908Gln) affects a highly conserved residue within the RL domain (Fig. S1).

Furthermore we identified four individuals bearing likely deleterious/loss-of-function variants. A heterozygous *de novo* frameshift variant, p.(Ala116Val*fs**12) in individual 22, a heterozygous nonsense variant, p.(Arg797*) in individual 23 inherited from a mosaic mother, a large heterozygous *de novo* deletion (chr3.hg19: g.(47,098,509-48,109,065)del) encompassing the whole *DHX30* gene in individual 24 (Fig. 1b and Fig. S3), and a *de novo* in-frame deletion encompassing exons 7-9 of *DHX30*, leading to. deletion of 381 amino acids, in individual 25. The whole gene deletion results in haploinsufficiency, whereas the in-frame deletion, frameshift and nonsense variant, if they were to result in stable proteins, are predicted to lead to loss of functionally important domains (Fig. 1a).

Notably, none of the novel *DHX30* alterations identified in our study were present in the gnomAD dataset[21] indicating that they are extremely rare in the population and unlikely to be alterations unrelated to disease. Furthermore, the degree of intolerance to deleterious variants of *DHX30* according to the Residual Variation Intolerance (RVI) score, which quantifies gene intolerance to functional mutations, is -1.51 (3.54[th] percentile) and thus even lower than the average RVI score for genes involved in developmental disorders (0.56; 19.54[th]th percentile).[22, 23]

Clinical spectrum of the *DHX30*-associated neurodevelopmental disorders

All 19 individuals harboring a heterozygous missense variant within a highly conserved motif in the helicase core domain have global developmental delay (GDD), intellectual disability (ID), severe speech impairment and gait abnormalities, similar to our initial findings.[8] In more detail, all individuals had intellectual disability, only nine (47%) learned to walk, all with an ataxic gait. The majority had no speech (74%), four individuals spoke only single words, and only individual 6, who is mosaic for the *de novo* p.(Ala734Asp) variant, spoke simple sentences. It is worth noting that the individuals highly profit from communication devices (tablets, smartphones and eye-driven tablet communication systems) significantly reduced frustration related behavior (D.L. personal communication with legal guardians and family members). Additional phenotypic features included muscular hypotonia in eighteen (95%), feeding difficulties in sixteen (84%), microcephaly in thirteen (81%, 13/16), joint hypermobility in fourteen (74%), structural brain anomalies in eleven (65%, 11/17), sleep disturbances in nine (47%), strabismus in eight (42%), autistic features in five (33%, 5/15) and seizures in four (21%) individuals (Table 1, Table S1 and supplementary data). Noteworthy, individual 6 had a relatively milder clinical course, with a moderate intellectual disability, independent walking at 2 years and 8 months and the ability to speak in simple sentences at the age of 15 years. This individual´s presentation is similar to the four individuals (#22, #23, #24 and #25), who carry either a frameshift or nonsense variant, whole-gene deletion or in-frame deletion, respectively, who all learned to walk in the second year of life, had a mild muscular hypotonia and spoke at least 20 words by the age of 3 years. Although some individuals displayed some dysmorphic features (supplementary data)we did not observe a recognizable facial pattern, similar to our previous findings.[8]

Two individuals (#4 and #21) clearly stand out phenotypically. Individual 4 washomozygous for p.(Arg725His), developed early-onset infantile epileptic encephalopathy and died in the early infancy. In contrast, individual 21, who harbors the *de novo* p.(Arg908Gln), had unremarkable psychomotor development until the age of 8 years when she presented with progressive balance impairment with truncal ataxia. Subsequently, she experienced a decline in motor skills and developed cognitive problems with reduced concentration (Table 1, Table S1 and supplementary data).

Effect of novel *DHX30* missense variants on ATPase activity.

To corroborate the pathogenicity of the novel missense variants identified in this study, along with the recently reported p.(Ser737Phe),[11] we performed several previously established functional assays.[8] First we analyzed the ATPase activity of wild-type (wt) and mutant forms of DHX30. As previously shown DHX30-wt acts as an RNA-dependent ATPase, and its ATPase activity is strongly stimulated by addition of RNA.[8] In contrast, and similar to the previously analyzed mutants[8] all missense variants (p.(Gly462Glu), p.(Arg725His), p.(Ala734Asp), p.(Ser737Phe), p.(Thr739Ala), p.(Arg782Gln) and p.(Arg908Gln)) show a significant reduction in ATPase activity upon stimulation with exogenous RNA (Fig. 2a-c).

RNA helicase activity of *DHX30* is disrupted by missense variants within the helicase core motifs.

DHX30 has been classified as an RH due to the presence of the highly conserved motifs in its helicase core region and sequence similarity to other RHs. To confirm that it indeed possesses an RNA helicase activity we established an RNA unwinding assay for recombinant full length DHX30 purified from bacteria as a His_6-SUMO-tagged protein. As a substrate we used a synthetic [^{32}P]-labeled RNA molecule which carries a sequence with strong propensity to self-anneal and form a double helix. Analysis of this RNA substrate by non-denaturing PAGE showed a single band of low electrophoretic mobility, corresponding to the dimer linked by the double helical segment. This dimer could be resolved into a band of higher mobility, the monomer, by pre-incubation at 96°C (Fig 2d).. To identify the amount of the DHX30-wt necessary to resolve the dimeric form we performed a titration analysis from 1ng to 160ng. This analyses revealed that in the presence of ATP, 10ng of DHX30-wt was already sufficient to resolve the dimer into the monomeric form, confirming that DHX30 indeed possesses the ATP-dependent RNA helicase activity (Fig. 2d and Fig. S4). We next analyzed the impact of selected missense variants on the helicase activity, each affecting a different helicase core motif (p.(Gly462Glu) in motif I, p.(Arg493His) in motif Ia, p.(His562Arg) in motif II, p.(Ser737Phe) in motif V and p.(Arg785Cys) in motif VI) along with the p.(Arg908Gln) located in RL domain.All mutations within a HCM failed to unwind the RNA substrates in this assay, whereas the p.(Arg908Gln) mutant behaved similar to DHX30-wt (Fig. 2e). It is worth noting that we consequently failed to purify the p.(Arg725His) mutant protein product, and thus could not analyze its impact on the helicase activity.

Subcellular localization and effect on global translation of novel *DHX30* missense variants.

We have previously shown that the expression of mutant forms of DHX30 induces the formation of stress granules, concomitant with a global down-regulation of translation.[8] Therefore, we repeated this analyses for selected novel missense variants. Similar to the previous results,[8] we observed that mutants within a HCM, p.(Gly462Glu),p.(Ala734Asp) and p.(Ser737Phe), also strongly accumulated in cytoplasmic foci shown to be stress granules upon co-staining with Ataxin-2 (ATXN2). Expression of

the p.(Arg908Gln) mutant, however, resulted in localization to cytoplasmic aggregates that co-stained with Ataxin-2 in only 50% of the transfected cells. In contrast, p.(Arg725His) was mostly diffusely localized throughout the cytoplasm similar to the DHX30-wt (Fig. 3a and Fig. S5). Global translation was measured by incorporation of puromycin into nascent peptide chains, which can be visualized with a puromycin-specific antibody. Interestingly, expression of both the HCM mutants and the p.(Arg908Gln) mutant resulted in dramatically decreased puromycin incorporation, suggestive of global decrease in protein synthesis (Fig. 3a).

In-vivo analyses of selected *DHX30* missense variants.

Given the somewhat conflicting results of functional analyses of the p.(Arg725His) and p.(Arg908Gln), and to gain a better understanding of the impact of *DHX30* missense variants in vivo, we utilized a zebrafish model. Previous studies showed that overexpression of pathogenic alleles in zebrafish results in defective embryonic development.[24, 25] Thus, we overexpressed human wild-type DHX30 cDNA or DHX30 cDNA harboring selected missense variants, p.(Arg493His), p.(Arg725His), p.(Arg785Cys) and p.(Arg908Gln), in zebrafish using Tol2 transposition. Tol2 mRNA and pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 were co-injected into 1-cell stage zebrafish embryos. For analyses we selected embryos with strong cmlc2:EGFP expression which indicates a high level of transgene integration in somatic cells. Overexpression of DHX30-wt had no or little impact on zebrafish embryonic development: over 88% of embryos displayed normal development and morphology. However, expression of DHX30 harboring one of the missense variants resulted in developmental defects in 75-100% of embryos (Fig. 3b and Fig.S6), suggesting that these mutant alleles interfere with normal embryonic development and supporting the pathogenicity of p.(Arg725His) and p.(Arg908Gln).

Analyses of the nature of the *DHX30* missense variants.

Given the somewhat milder clinical presentation of individuals bearing either a whole gene deletion, in-frame deletion, a frameshift or a nonsense variant as compared to the individuals bearing a *de novo* missense variant in one of the HCMs, we further investigated the nature of the latter. First, we analyzed the localization of the RFP-tagged DHX30-wt co-expressed with respective GFP-tagged missense variants. Notably, their equimolar expression resulted in each case in DHX30-wt being localized in the Ataxin-2 positive cytoplasmic cluster (Fig. 4a and Fig. S7) suggesting that the missense variants might exert a dominant negative effect on the wild-type. Next, we analyzed if the DHX30-wt can rescue the inability of p.(Arg493His), p.(His562Arg) and p.(Arg785Cys) to unwind the RNA. Addition of DHX30-wt to p.(His562Arg) and p.(Arg785Cys) efficiently resolved the dimer into the monomeric form even in the presence of increased amounts of the respective mutants, whereas we observed only a partial rescue when DHX30-wt was added to the p.(Arg493His) (Fig. 4b). Given these somewhat contradictory results we turned again to the zebrafish model. We co-injected pTol2pA2-cmlc2:EGFP;tuba1a:DHX30 p.(Arg493His) or p.(Arg785Cys) with wild-type DHX30 cDNA and assessed embryonic development. Interestingly, co-injection of DHX30-WT, at similar extent, partially rescued the abnormal phenotypes

associated with both p.(Arg493His) and p.(Arg785Cys) (Fig. 4c), a finding that could potentially support both loss-of-function and a dominant negative effect as a mechanism underlying disease.

DISCUSSION

Our study has allowed further delineation of the clinical spectrum of *DHX30*- related neurodevelopmental disorders through analysis of 25 novel affected individuals, partially facilitated by the use of social media-based family support group. This case series highlights that global developmental delay, intellectual disability, severe speech impairment and gait abnormalities remain most prominent clinical features. We also identified microcephaly as an additional common clinical feature. Moreover, based on the clinical and molecular findings we suggest a classification in at least two different *DHX30*-associated neurodevelopmental disorder clinical subtypes. One subtype involving individuals bearing heterozygous missense variants affecting highly conserved residues within a HCM and with a severe phenotype, and a second displaying a somewhat milder phenotype due to either a mosaic missense variant within a HCM, haploinsufficiency or protein-truncating variants. It is also worth noting that our findings suggest evidence of a possible third and fourth clinical subtype: an early-onset infantile epileptic encephalopathy due to homozygous missense variants within the helicase core region, but not within a conserved motif, as observed in individual 4; and a late-onset progressive ataxia as observed in individual 21 due to heterozygous missense variants within the C-terminal regulatory domains. Although individuals 4 and 21 presented with clinical signs and symptoms observed in other affected individuals, suggestive of a phenotypic continuum, it is worth noting that at this point we cannot exclude the possibility that they carry additional variants with phenotypic consequences. Further work, especially identification of additional affected individuals carrying similar variants is needed to confirm the latter hypotheses.

Identification of affected individuals with a milder phenotype challenges naming of this disorder "Neurodevelopmental disorder with severe motor impairment and absent language" (NEDMIAL; OMIM # 617804). Notably, only 9 of the 25 individuals (36%) presented here had a severe motor impairment (never learned to walk) and 9 out of 25 individuals (36%) spoke at least single words, thus did not have a completely absent language. Therefore we suggest naming these conditions as *DHX30-*associated neurodevelopmental disorders in the future.

To provide further evidence for the pathogenicity of the novel missense *DHX30* variants and possibly gain better insight into their pathogenic role we performed several *in-vitro* and *in-vivo* assays. All novel missense variants within a HCM resulted in impaired ATPase activity (all were within an ATP binding and hydrolysis motif), and increased propensity to trigger stress granule (SG) formation resulting in inhibition of global translation, as expected from the previous study.[8] In addition, we have now formally confirmed that DHX30 possesses ATP-dependent RNA helicase activity, which is impaired by the HCM missense variants. Notably, we present here the first homozygous missense variant, p.(Arg725His), located within the helicase core region, but not in a HCM. This variant does lead to reduced ATPase activity but does not lead to SG hyper-assembly with concomitant global translation impairment; however the impact conferred on helicase activity could not be evaluated. Given that the

biallelic variant was inherited from unaffected heterozygous parents may indicate that similar heterozygous missense variants may not be disease-causing. However, further work involving both identification of additional individuals harboring similar variants along with rigorous functional analyses are needed.

Based on homology to other SF2´s we have identified three evolutionary conserved C-terminal regulatory domains, a winged helix domain (WHD), a ratchet-like (RL) and an oligosaccharide binding (OB) fold domain (Fig. 1) with a potential role in coupling ATP hydrolysis to RNA unwinding.[20] Functional characterization of a missense variant, p.(Arg908Gln), affecting a highly conserved residue within the RL domain, revealed that this variant impairs the ATPase but not helicase activity of DHX30. This finding suggests that RL is required for helicase independent ATP hydrolysis. Whereas this variant leads to formation of aberrant cytoplasmic aggregates, unlike the missense variants within HCM not all aggregates/foci could be confirmed to be translationally silent SGs. Clearly, further experimental work is necessary to delineate the role of the DHX30 C-terminal domains along with further investigation of these seemingly non-SGs but translationally active aggregates.

We have previously suggested that the missense variants within HCM might have a more severe effect than a loss of one gene copy.[8] This hypothesis is now supported by identification of four affected individuals carrying variants that result in either haploinsufficiency or a truncated protein, all of whom presented with a milder phenotype as compared to the individuals bearing missense variants within HCM. One possibility is that these missense variants exert a dominant negative effect. However, arguing against such an effect is the fact that there is not a single individual bearing a homozygous non-synonymous *DHX30* variant documented in the gnomAD dataset, accompanied by the fact that homozygous disruption of murine HelG/Dhx30 results in early embryonic lethality.[26] Another possibility would be that these missense variants result in a partial or moderate gain of function. Interestingly, the fact that equimolar expression of several of these missense variants together with the DHX30-wt, resulted in recruitment of wt into SG´s might suggest a dominant negative effect. However, it is worth noting that DHX30-wt, as well as the endogenous protein, are recruited to the SG´s after stress induction.[8] Thus, the missense variants might result in a detrimental gain-of-function by inducing the SG formation with concomitant global translation impairment even without endogenous or exogenous stressors. Another possibility is that the actual transient transfection of these missense variants "per se" generates stress resulting in SG hyper-assembly. Further analyses, primarily those aiming to investigate the potential role of DHX30 in assembly of SGs are needed to resolve this. While performing the helicase assay we observed somewhat conflicting results, as addition of DHX30-wt to even increasing amounts of p.(His562Arg) and p.(Arg785Cys) completely resolved the dimer. However, this could only be partially achieved when DHX30-wt was added to p.(Arg493His). Analyses of the effect on early zebrafish development also produced results that could be interpreted both ways, suggesting that p.(Arg493His) and p.(Arg785Cys) result in a dominant negative effect, or opposing this hypothesis. Another possibility is that these missense variants result, if only partially, in a gain-of-

function. Indeed, they might result in acquisition of novel and different RNA and even miRNA binding sites. However, analyses delineating the abovementioned will require extensive further work and will be the main aim of our future studies.

CONCLUSION

The identification of 25 novel affected individuals has expanded the clinical and genetic spectrum of *DHX30*-associated neurodevelopmental disorder, and suggest existence of clinically distinct subtypes correlating with location and nature of pathogenic variants. Our study highlights the usefulness of social media-based family support groups as a resource in defining ultra-rare disorders as well as the need for *in-depth* functional characterization of potentially pathogenic variants. We further confirmed DHX30 to be an ATP-dependent RNA helicase and identified novel conserved C-terminal domains. Additional studies are required to further delineate the variety of clinical outcomes underlying different *DHX30* variants, as well as the roles of DHX30 in various aspects of RNA metabolism along with clarification of the nature of pathogenic missense variants.

AUTHORS' CONTRIBUTIONS

I.M., N.C.Y., H.H., N.D.P.D., U.F., H-J.K. and D.L. generated and analyzed the functional data. D.L. and H-J.K. supervised the study. D.L. wrote the manuscript. J.B.M., J.A., T.A., S.B., G.B., D.B., A.B., P.J.B., S.B., T.B., F.B., L.A.B., G.J.B., Ø.L.B, J.C., J.D., L.F.E., C.E., J.F., D.G., C.A.H., M.H., Y.H-M., G.H., A.J., L.K., B.K., C.K-B., C.Kr., C.Ku., G.L.G., U.W.L, L.M.B, J.A.M-A., M.M., D.T.M., K.Q.M., B.M., C.N., S.F.N., T.P., F.R., H.R., S.F.R., J.S-H., P.B.S, A.S., S.S., A.P.A.S., K.To., K.Tv., J.H.W., C.Z., K.M., J.J., F.Q-R. identified and collected patients. All authors have read and approved the final manuscript.

COMPETING INTERESTS

K.M. and J.J. are employees of GeneDx, Inc.

ACKNOWLEDGEMENTS

We thank all family members for their participation and collaboration, Hans-Hinrich Hönck (Institute for Human Genetics, UKE Hamburg) for technical assistance, and UKE microscopic imaging facility (umif) for providing assistance with confocal microscopes. This work was funded in part by Werner Otto Stiftung (to D.L and H-J.K) and Deutsche Forschungsgemeinschaft (LE4223/1-1 to D.L.; Kr1321/8-2 to H-J.K), by the UCLA Pathology Translational Research Fund (to J.B.M. and F.Q-R.) and by the UCLA California Center for Rare Diseases (to S.F.N).

References:

1. Jankowsky E: **RNA helicases at work: binding and rearranging.** *Trends Biochem Sci* 2011, **36:**19-29.
2. Linder P, Jankowsky E: **From unwinding to clamping - the DEAD box RNA helicase family.** *Nat Rev Mol Cell Biol* 2011, **12:**505-516.
3. Umate P, Tuteja N, Tuteja R: **Genome-wide comprehensive analysis of human helicases.** *Commun Integr Biol* 2011, **4:**118-137.
4. Heerma van Voss MR, van Diest PJ, Raman V: **Targeting RNA helicases in cancer: The translation trap.** *Biochim Biophys Acta Rev Cancer* 2017, **1868:**510-520.
5. Cai W, Xiong Chen Z, Rane G, Satendra Singh S, Choo Z, Wang C, Yuan Y, Zea Tan T, Arfuso F, Yap CT, et al: **Wanted DEAD/H or Alive: Helicases Winding Up in Cancers.** *J Natl Cancer Inst* 2017, **109**.
6. Snijders Blok L, Madsen E, Juusola J, Gilissen C, Baralle D, Reijnders MR, Venselaar H, Helsmoortel C, Cho MT, Hoischen A, et al: **Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling.** *Am J Hum Genet* 2015, **97:**343-352.
7. Balak C, Benard M, Schaefer E, Iqbal S, Ramsey K, Ernoult-Lange M, Mattioli F, Llaci L, Geoffroy V, Courel M, et al: **Rare De Novo Missense Variants in RNA Helicase DDX6 Cause Intellectual Disability and Dysmorphic Features and Lead to P-Body Defects and RNA Dysregulation.** *Am J Hum Genet* 2019, **105:**509-525.
8. Lessel D, Schob C, Kury S, Reijnders MRF, Harel T, Eldomery MK, Coban-Akdemir Z, Denecke J, Edvardson S, Colin E, et al: **De Novo Missense Mutations in DHX30 Impair Global Translation and Cause a Neurodevelopmental Disorder.** *Am J Hum Genet* 2017, **101:**716-724.
9. Shamseldin HE, Rajab A, Alhashem A, Shaheen R, Al-Shidi T, Alamro R, Al Harassi S, Alkuraya FS: **Mutations in DDX59 implicate RNA helicase in the pathogenesis of orofaciodigital syndrome.** *Am J Hum Genet* 2013, **93:**555-560.
10. Paine I, Posey JE, Grochowski CM, Jhangiani SN, Rosenheck S, Kleyner R, Marmorale T, Yoon M, Wang K, Robison R, et al: **Paralog Studies Augment Gene Discovery: DDX and DHX Genes.** *Am J Hum Genet* 2019, **105:**302-316.
11. Cross LA, McWalter K, Keller-Ramey J, Henderson LB, Amudhavalli SM: **A report of gonadal mosaicism in DHX30-related neurodevelopmental disorder.** *Clin Dysmorphol* 2020, **29:**161-164.
12. Sobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A: **New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene.** *Hum Mutat* 2015, **36:**425-431.
13. Guenther UP, Handoko L, Laggerbauer B, Jablonka S, Chari A, Alzheimer M, Ohmer J, Plottner O, Gehring N, Sickmann A, et al: **IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1).** *Hum Mol Genet* 2009, **18:**1288-1300.
14. Tseng-Rogenski SS, Chang TH: **RNA unwinding assay for DExD/H-box RNA helicases.** *Methods Mol Biol* 2004, **257:**93-102.
15. Tanner NK, Linder P: **DExD/H box RNA helicases: from generic motors to specific dissociation functions.** *Mol Cell* 2001, **8:**251-262.
16. Caruthers JM, McKay DB: **Helicase structure and mechanism.** *Curr Opin Struct Biol* 2002, **12:**123-133.
17. Buttner K, Nehring S, Hopfner KP: **Structural basis for DNA duplex separation by a superfamily-2 helicase.** *Nat Struct Mol Biol* 2007, **14:**647-652.
18. Tauchert MJ, Fourmann JB, Luhrmann R, Ficner R: **Structural insights into the mechanism of the DEAH-box RNA helicase Prp43.** *Elife* 2017, **6**.
19. Prabu JR, Muller M, Thomae AW, Schussler S, Bonneau F, Becker PB, Conti E: **Structure of the RNA Helicase MLE Reveals the Molecular Mechanisms for Uridine Specificity and RNA-ATP Coupling.** *Mol Cell* 2015, **60:**487-499.

20. Murakami K, Nakano K, Shimizu T, Ohto U: **The crystal structure of human DEAH-box RNA helicase 15 reveals a domain organization of the mammalian DEAH/RHA family.** *Acta Crystallogr F Struct Biol Commun* 2017, **73:**347-355.
21. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, et al: **The mutational constraint spectrum quantified from variation in 141,456 humans.** *Nature* 2020, **581:**434-443.
22. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB: **Genic intolerance to functional variation and the interpretation of personal genomes.** *PLoS Genet* 2013, **9:**e1003709.
23. Hempel M, Cremer K, Ockeloen CW, Lichtenbelt KD, Herkert JC, Denecke J, Haack TB, Zink AM, Becker J, Wohlleber E, et al: **De Novo Mutations in CHAMP1 Cause Intellectual Disability with Severe Speech Impairment.** *Am J Hum Genet* 2015, **97:**493-500.
24. Davis EE, Frangakis S, Katsanis N: **Interpreting human genetic variation with in vivo zebrafish assays.** *Biochim Biophys Acta* 2014, **1842:**1960-1970.
25. Finckbeiner S, Ko PJ, Carrington B, Sood R, Gross K, Dolnick B, Sufrin J, Liu P: **Transient knockdown and overexpression reveal a developmental role for the zebrafish enosf1b gene.** *Cell Biosci* 2011, **1:**32.
26. Zheng HJ, Tsukahara M, Liu E, Ye L, Xiong H, Noguchi S, Suzuki K, Ji ZS: **The novel helicase helG (DHX30) is expressed during gastrulation in mice and has a structure similar to a human DExH box helicase.** *Stem Cells Dev* 2015, **24:**372-383.

Figure legends:

Figure 1. Location of identified *DHX30* germline alterations.

(**A**) Highly conserved sequence motifs within the helicase core region are shown with color coding that corresponds to the primary function of the motif (as previously described by Lessel *et al.*, 2017). Double stranded RNA-binding domains (dsRBD) 1 and 2 at the N-terminus (N-) are shown in grey. A winged helix domain (WHD), a ratchet-like (RL) domain and an oligosaccharide binding (OB) domain are shown in yellow at the C-terminus (-C). The position of the first and last amino acid within each motif/domain is indicated below. Previously reported heterozygous missense variants and newly identified *DHX30* variants are denoted in grey and black, respectively. Frameshift and nonsense variants are denoted in blue. Mutated amino acid residues within the helicase core region are marked in red. The position of previously and newly identified mutations are indicated with red arrows. (**B**) Genomic region, chr3.hg19:g.(47098509-48109065)del, of the ~1 Mb deletion identified in case 24.

Figure 2. Protein variants of *DHX30* affect either ATPase or helicase activity.

(**A, B and C**) ATPase assays were performed for DHX30-WT and novel DHX30 variants in the presence and absence of exogenous RNA. In each case, ATPase activity was calculated by subtracting phosphate values obtained with GFP alone from those obtained with GFP-tagged DHX30-WT and mutants. These figures were then normalized on precipitated protein amounts using the optical density values of the GFP signal in the western blot. Means ± Standard Deviation values are based on 3 replications. ***,****: significantly different from DHX30-WT (***$p<0.001$;****$p<0.0001$; n=3; Two-Way ANOVA, followed by Dunnett's multiple comparisons test). Values were normalized on DHX30-WT ATPase activity obtained in the presence of RNA. (**D**). Increasing amounts of His$_6$-SUMO-tagged DHX30 WT protein were incubated with a [^{32}P]-labelled RNA substrate in the presence (lane 3-7) or absence (lane 8) of ATP and analyzed by native PAGE. The position of the RNA duplex and the single-stranded RNA are indicated in the first and second lane respectively. Their schematic representation is shown at the right side. (**E**) Helicase assay was repeated for selected DHX30 missense variants affecting either conserved motifs within the helicase core region (lane 4-8) or the auxiliary RL domain (lane 9).

Figure 3. Protein variants of *DHX30* initiate the formation cytoplasmic aggregates and impair global translation, and lead to embryonal developmental defects in zebrafish.

(**A**) Puromycin incorporation assay in U2OS cells expressing DHX30-GFP fusion proteins (green). Translation was monitored by staining against puromycin (red), SGs were detected by ATXN2 (magenta) and nuclei via DAPI staining (blue). Arrows indicate transfected cells. Note the correlation between formation of clusters and lack of puromycin staining. Scale bars indicate 10 µm. (**B**) *In-vivo* analyses of selected DHX30 missense variants. Assessment of embryionic development after injection of DHX30-wt and mutant cDNAs in a zebrafish model. Bar graph indicating the percentage of cmcl2-GFP positive zebrafish embryos 4-7 days postfertilization (dpf).

Figure 4. Analyses of the nature of missense variants within the helicase core motifs (HCM).

(**A**) Immunocytochemical detection of RFP-DHX30 WT (red) and ATXN2 (magenta) after co-expression of DHX30-GFP mutants (green) in U2OS cells. Nuclei are identified via DAPI staining (blue). Note that upon overexpression of DHX30-GFP WT or GFP alone, RFP-DHX30 WT showed a mostly diffused cytoplasmic distribution. Arrowheads denote colocalization of RFP-DHX30 WT and DHX30-GFP mutants within SGs. Scale bars indicate 10 µm. (**B**) RNA unwinding activity of purified DHX30 R493H, H562R and R785C mutants was analyzed upon addition of DHX30 WT protein. Increasing amounts of mutant proteins were incubated with 20 ng of WT protein and assayed for their ability to unwind a radiolabeled RNA duplex in the presence of ATP. (**c**) Assessment of embryonic development after co-injection of DHX30 R493H and R785C with DHX30 WT cDNA in a zebrafish model. Bar graph indicating the percentage of cmcl2-GFP positive zebrafish embryos 4-7 days postfertilization (dpf).

Table 1. Clinical features in 25 individuals bearing pathogenic *DHX30* variants and frequency of these features in previously reported individuals.

a

Helicase core region

N- | dsRBD1 | dsRBD2 | | I | Ia | Ib | II | III | | IV | V | VI | | WHD | RL | OB | -C

1 | 53 | 145 | 245 | 264 | 338 | | | | | | 643 | | | | | 809 | 878 | 879 | 940 | 1016 | 1102 | 1194

Motif I | Motif Ia | Motif Ib | Motif II | Motif III | Motif IV | Motif V | Motif VI

GDTGCGKT | ITQPRRISAVS | FCTVGILLRK | IVDEVHER | SAT | LCFLPG | TNIAETSITIND | VIQRRGRAGRCQ

457 | 464 | 488 | 498 | 534 | 543 | 557 | 564 | 591 | 593 | 672 | 677 | 731 | 742 | 776 | 787

R493H
2 cases

H562R
1 case

S737F
2 cases

G781D
2 cases

R782W
3 cases

R785C
3 cases

R785H
1 case

A116Vfs*12
1 case

Exon 7-9 del
(381 aa del)
1 case

G462E
1 case

R493H
1 case

H562R
1 case

R725H
1 case
(homozygous)

A734D
2 cases

T739A
1 case

R782W
5 cases

R782Q
3 cases

R785C
4 cases

R785H
1 case

R797*
1 case

R908Q
1 case

b

chr3 (p21.31)

SETD2 | KIF9 KLHL18 | PTPN23 SCAP | ELF6 | CSPG5 SMARCC1 | DHX30 MAP4

a

	GFP	Puromycin	ATXN2	merge
DHX30-WT				
G462E				
R725H				
A734D				
S737F				
R908Q				
GFP				

b

DHX30 alteration	Heterozygous missense variants within a HCM (this study)	p.(Ala734Asp) mosaic (this study)	Haploinsufficiency / protein truncating variants (this study)	Homozygous p.(Arg725His) (this study)	Heterozygous p.(Arg908Gln) (this study)	Heterozygous missense variants within a HCM (previous studies: Lessel *et al.* 2017 & Cross *et al.* 2020)
Sex	11 female / 7 male	female	1 female / 3 male	male	female	8 female / 6 male
Intellectual disability	18 / 18	+	4 / 4	?	-	13 / 13
Speech ability	14 / 18 non-verbal 4 / 18 single words	simple sentences	20 word to normal speech ability	?	normal speech ability	11 /13 non-verbal 2/ 13 single words
Motor development delay	18 / 18	+	4 / 4 mild	+	-	14 / 14
Muscular hypotonia	17 / 18	+	3 / 4	+	-	14 / 14
Gait abnormalities	10 / 18 no independent walking 8 / 18 ataxic	ataxic gait	0 / 4 no independent walking 3 / 4 ataxic gait	?	ataxic gait	7 / 13 no independent walking 6 / 13 ataxic gait
Feeding difficulties	15 / 18	+	1 / 4	+	-	11 / 14
Microcephaly	13 / 15	+	0 / 4	-	-	7 / 10
Joint hypermobility	13 / 18	+	1 / 3	-	-	6 / 14
Brain MRI anomalies	11 / 17	-	2 / 3	+	+	10 / 14
Sleep disturbance	8 / 18	+	2 / 3	+	-	7 / 12
Strabismus	8 / 18	-	2 / 4	-	+	6 / 14
Autistic features	4 / 14	+	0 / 3	?	-	7 / 12
Seizures	3 / 18	+	2 / 3	severe	-	3 / 14

+, present; -, absent; ?, too young to evaluate; NA, unkown

Table 1: Clinical features in 25 individuals bearing pathogenic *DHX30* variants and frequency of these features in previously reported individuals.